Catheter Closure of Moderate- to Large-Sized Patent Ductus Arteriosus Using the New Amplatzer Duct Occluder: Immediate and Short-Term Results

Mašura, Jozef; Walsh, Kevin; Thanopoulous, Basil; Chan, Chen; Bass, John L.; Goussous, Yousef; Gavora, Paul; Hijazi, Ziyad M.

doi:10.1016/s0735-1097(98)00013-8

Cited by 304 publications

(224 citation statements)

References 12 publications

Supporting

Mentioning

206

Contrasting

Unclassified

Order By: Relevance

“…Some publications report routine use of procedural UFH for closure of the patent ductus arteriosus, 674 whereas other series do not comment on the use of thromboprophylaxis at all 675 or refer to variable use according to operator preference. 676 No study has evaluated the efficacy of and need for procedural thromboprophylaxis for patent ductus arteriosus device or coil closure. Many centers use a lower dose of procedural thromboprophylaxis (ie, 50 U/kg heparin).…”

Section: Thromboprophylaxis Of Transcatheter Embolization Proceduresmentioning

confidence: 99%

Prevention and Treatment of Thrombosis in Pediatric and Congenital Heart Disease

Giglia¹,

Massicotte²,

Tweddell³

et al. 2013

Circulation

297

245

View full text Add to dashboard Cite

Section: Thromboprophylaxis Of Transcatheter Embolization Proceduresmentioning

confidence: 99%

Prevention and Treatment of Thrombosis in Pediatric and Congenital Heart Disease

Giglia¹,

Massicotte²,

Tweddell³

et al. 2013

Circulation

297

245

View full text Add to dashboard Cite

“…The prosthesis is available in 5 combinations of diameters in 7mm or 8mm lengths. The profile of the sheath ranges form 5 Fr to 7 Fr, according to the diameter selected [1][2][3][4][5] . A great technical advantage of this implantation system is the possibility of rescuing the prosthesis inside the sheath, if its location is not adequate, before its final delivery, and this procedure is totally controlled by the operator.…”

Section: Discussionmentioning

confidence: 99%

“…A great technical advantage of this implantation system is the possibility of rescuing the prosthesis inside the sheath, if its location is not adequate, before its final delivery, and this procedure is totally controlled by the operator. The world clinical experience and that in Brazil show a 100% efficacy for occlusion of ductus arteriosus with very low indices of complications [2][3][4][5] . Due to the favorable characteristics of the system, this prosthesis has also been used to occlude other vascular structures [6][7][8] .…”

Section: Discussionmentioning

confidence: 99%

“…Based on the publication of results of convincing experimental studies 1 , the new Amplatzer device for percutaneous occlusion of ductus arteriosus (AGA Medical Corporation, Golden Valley, MN, USA) has been shown to be safe and highly effective in clinical practice [2][3][4][5] . Due to the versatility of the implantation system and the characteristics of the prosthesis, it has also been used for occlusion of other defects and vascular malformations, such as coronary and pulmonary arteriovenous fistulae, systemic-pulmonary shunts (Blalock-Taussig), venovenous collaterals after Glenn surgery, tubes, fenestrated Fontan, and others [6][7][8] .…”

mentioning

confidence: 99%

See 1 more Smart Citation

A New Use for the Amplatzer Duct Occluder Device

Pedra¹,

Sousa²,

Pilla³

et al. 2002

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

We report a case in which the Amplatzer device for percutaneous occlusion of ductus arteriosus was successfully used for occluding a large systemic-pulmonary collateral vessel in a patient who had previously undergone surgery for correction of pulmonary atresia and ventricular septal defect (Rastelli technique), and was awaiting the change of a cardiac tube. In the first attempt, the device embolized to the distal pulmonary bed and, after being rescued with a Bitome, it was appropriately repositioned with no complications and with total occlusion of the vessel.Based on the publication of results of convincing experimental studies 1 , the new Amplatzer device for percutaneous occlusion of ductus arteriosus (AGA Medical Corporation, Golden Valley, MN, USA) has been shown to be safe and highly effective in clinical practice [2][3][4][5] . Due to the versatility of the implantation system and the characteristics of the prosthesis, it has also been used for occlusion of other defects and vascular malformations, such as coronary and pulmonary arteriovenous fistulae, systemic-pulmonary shunts (Blalock-Taussig), venovenous collaterals after Glenn surgery, tubes, fenestrated Fontan, and others 6-8 . We report a case in which this device was successfully used for closure of a large systemic-pulmonary collateral vessel originating from the descending aorta. Case ReportThe patient is a 17-year-old male who underwent surgical repair of pulmonary atresia, ventricular septal defect, and systemic-pulmonary collaterals at the age of 7 years. The collaterals were focalized, the ventricular septal defect was occluded with a patch of bovine pericardium and an 18-mm Dacron tube graft, which was used to reestablish the continuity between the right ventricle and the pulmonary artery (Rastelli technique). The patient complained of mild fatigue on exertion, and on physical examination an ejective systolic murmur in the middle left sternal margin and a continuous murmur in the dorsum could be heard. On chest X-ray, slight cardiomegaly and increased pulmonary flow to the right middle and lower lobes were observed. The electrocardiogram showed sinus rhythm and biventricular hypertrophy. The twodimensional Doppler color flow echocardiogram showed signs of obstruction of the tube with rectification of the ventricular septum during systole. Right ventricular pressure was estimated in approximately 3/4 of the arterial blood pressure through tricuspid reflux. Moderate pulmonary insufficiency also existed. The patient was referred for cardiac catheterization for diagnostic complementation, and the examination, performed with the patient under local anesthesia, showed the following pressure levels (in mm Hg): right atrium, 9; right ventricle, 90/10; pulmonary artery, 30/11; left ventricle, 110/12; and aorta, 110/ 60. Right ventriculography revealed obstruction of the tube in its proximal portions, next to the right ventricular musculature, and mild to moderate systolic dysfunction. The aortogram, followed by selective injection in the vessel, sho...

show abstract

“…5 In 1992, Combier 6 first reported successful closure of PDA with coils that began to be widely applied throughout the world. 7 In 1997, this occluder was greatly improved by Amplatzer, and so was born a new generation of coils named Amplatzer. From that time on, the efficiency and safety of transcatheter interventional treatment of congenital heart disease have been greatly improved.…”

Section: Introductionmentioning

confidence: 99%

Clinical Efficiency and Safety Analysis of Transcatheter Interventional Therapy for Compound Congenital Cardiovascular Abnormalities

Zhang

Maoqin

et al. 2007

Clinical Cardiology

View full text Add to dashboard Cite

Objective: To investigate the efficiency and safety of transcatheter interventional therapy for compound congenital cardiovascular abnormalities. Methods: From Nov 2001 to Jun 2006, a total of 36 patients (17 male, 19 female), aged 17.20 ± 10.52, with compound congenital cardiovascular abnormalities underwent transcatheter interventional procedure. These patients included 11 with perimembranous ventricular septal defect (PVSD) and patent ductus arteriosus (PDA), 8 patients with PVSD and atrial septal defect (ASD), 8 patients with ASD and PDA, 7 patients with ASD and pulmonary stenosis (PS), 1 patient with ASD and mitral stenosis(MS), 1 patient with coarctation of aorta (COA) and PDA. According to the principle of “easy first, hard second,” balloon valvuloplasties of PS or MS were performed before the closure of PVSD, and of PDA and ASD. Electrocardiogram and transthoracic echocardiogram were examined at 4 days, 1, 2, 6 and 12 months, respectively, after each procedure. Results: Transcatheter interventional therapy for compound congenital cardiovascular abnormalities was successful in all patients. Among these, 2 occluders were planted in each of 27 patients, 7 patients with ASD combined with PS and 1 patient with ASD combined with MS underwent successfully performed balloon valvuloplasty and ASD closure, 1 patient with COA combined with PDA underwent successfully performed balloon valvuloplasty and subsequent covered stent implantation. No patient encountered serious adverse events during the (30.5 ± 14.6) months of follow‐up. Conclusions: Transcatheter interventional therapy for compound congenital cardiovascular abnormalities could obtain satisfactory results with technical feasibility. Copyright © 2007 Wiley Periodicals, Inc.

show abstract

Catheter Closure of Moderate- to Large-Sized Patent Ductus Arteriosus Using the New Amplatzer Duct Occluder: Immediate and Short-Term Results

Abstract: Anterograde transcatheter closure using the new ADO is an effective therapy for patients with a PDA diameter up to 6 mm. Further clinical trials are underway.

Cited by 304 publications

References 12 publications

Prevention and Treatment of Thrombosis in Pediatric and Congenital Heart Disease

Prevention and Treatment of Thrombosis in Pediatric and Congenital Heart Disease

A New Use for the Amplatzer Duct Occluder Device

Clinical Efficiency and Safety Analysis of Transcatheter Interventional Therapy for Compound Congenital Cardiovascular Abnormalities

Contact Info

Product

Resources

About